Interestingly, clinicopathologic and laboratory characteristics at the baseline were similar in patients with NASH-driven HCC and patients with no NASH-driven HCC, with the exception of the ALBI grade and AFP. This evidence concerns the gene AFP and metabolic dysfunction-associated steatohepatitis.